Acneiform Eruption with Deucravacitinib: Systematic Review and Meta-Analysis

Clicks: 1
ID: 320540
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #154 of 171 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 171 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Deucravacitinib, an oral selective tyrosine kinase 2 (TYK2) inhibitor, is an effective treatment for chronic plaque psoriasis. Its use is widening to treat other autoinflammatory conditions, but acneiform eruptions have been increasingly reported. The objective was to quantify the incidence of acneiform eruptions with deucravacitinib and compare odds versus placebo, with exploratory analyses by dose and indication. A search of Medline, Embase, and CENTRAL was made for interventional and observational studies. Primary outcome was incidence of acneiform eruption (acne, folliculitis, dermatitis acneiforme, rosacea). Random-effects meta-analysis pooled proportions and odds ratios (OR) was performed. Of 672 records, 14 studies met inclusion. Overall, 467/5,280 (8.8%) developed an acneiform eruption (acne 71.3%, folliculitis 23.3%, dermatitis acneiforme 3.2%, rosacea 2.1%). Across eight controlled studies, pooled incidence was 6.4% (95% CI: 0.05 - 0.09; I2 = 74.9%). Events occurred in 145/2,539 (5.71%) on deucravacitinib versus 9/1,070 (0.84%) controls; pooled OR 4.56 (95% CI 2.28–9.12; I2=9.4%). Discontinuations for acneiform events were uncommon (7/3,317; 0.21%). Dose- and indication-specific analyses suggested higher odds at greater total daily doses and in psoriasis/inflammatory bowel disease. In conclusion, acneiform eruptions are a frequent cutaneous adverse event with deucravacitinib and occur significantly more often than with placebo yet rarely lead to discontinuation.
Reference Key
openalex_W7167942757 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors James Gaston, Andrew Maxwell, Hieu Chi Ha, Anna Antony, Francis Yi Xing Lai, Senhong Lee
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag286
URL
https://doi.org/10.1093/ced/llag286
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.